Ubs Group Ag Belite Bio, Inc Transaction History
Ubs Group Ag
- $527 Billion
- Q4 2024
A detailed history of Ubs Group Ag transactions in Belite Bio, Inc stock. As of the latest transaction made, Ubs Group Ag holds 12,207 shares of BLTE stock, worth $690,549. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,207
Previous 128
9436.72%
Holding current value
$690,549
Previous $6,000
12733.33%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BLTE
# of Institutions
24Shares Held
278KCall Options Held
0Put Options Held
0-
Armistice Capital, LLC New York, NY168KShares$9.5 Million0.15% of portfolio
-
State Street Corp Boston, MA20KShares$1.13 Million0.0% of portfolio
-
Bank Of America Corp Charlotte, NC18.3KShares$1.04 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY14.6KShares$827,9580.0% of portfolio
-
Morgan Stanley New York, NY10.6KShares$600,6600.0% of portfolio
About BELITE BIO, INC
- Ticker BLTE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,867,400
- Market Cap $1.41B
- Description
- Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...